U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
South Korea’s KOSPI Plunges as Apple Price Hikes and OpenAI IPO Delay Shake AI Chip Stocks 
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Wall Street Ends Mixed as Micron Surges, Apple Drops After Price Hikes 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Asian Markets Rally as Micron and Qualcomm AI Outlook Lifts Global Tech Stocks 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Australia Jobs Growth Strengthens Rate Hike Outlook 
US Dollar Slips After PCE Inflation Data Eases Fed Rate Hike Expectations 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Merck & Co. is said to be in advanced talks for the acquisition of Seagen, a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Fox Business reported that the acquisition deal could be valued at almost $40 billion. The amount could be more as the share price for Seagen is above $200 per share. The deal will help Merck & Co. with its expansion efforts as it adds a new acquisition to its cancer drug portfolio.
Currently, Merck’s highest-selling product is its Keytruda immunotherapy drug. The Rahway, New Jersey pharmaceutical company said that this drug accounted for $17.2 billion worth of its sales last year. As for Seagen, some of its best-selling products include Adcetris, which gathered total sales of $1.4 billion last year.
In any case, while Merck and Seagen are already in the advanced stage of negotiations, it was noted that there is still no assurance that they will be reaching an agreement for the sale of the latter.
Moreover, it was mentioned that any proposed deal in this negotiation is also expected to draw a close look from antitrust regulators. Both Merck and Seagen are still hoping to finally sign an agreement on or before Merck announces its second fiscal-quarter earnings, which has been scheduled for July 28.
Reuters reached out to Merck for comments regarding the acquisition reports, but it was not able to respond to the request immediately. On the other hand, Seagen was said to have declined to comment.
As of Wednesday, July 6, the companies are still discussing a price above $200 per share, and on that day, its closing share price was actually $175. It was added that Seagen has a market capitalization of $32.24 billion based on the records from Refinitiv data.
Meanwhile, industry observers believe that it will make sense if Merck & Co. is able to close its deal with Seagen for $250 or below. This is because this acquisition will definitely boost the company’s business and strengthen its portfolio through the latter’s exclusive cancer immunotherapy drug, Keytruda.
